Cargando…

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first interim analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Gupta, Neeraj, Hanley, Michael J., Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605398/ https://www.ncbi.nlm.nih.gov/pubmed/32780660 http://dx.doi.org/10.1200/JCO.20.00505

Ejemplares similares

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
por: Gettinger, Scott N., et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
por: Gupta, Neeraj, et al.
Publicado: (2022)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2023)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
por: Jiang, Wei, et al.
Publicado: (2020)

Novel ALK mutation with durable response to brigatinib—a case report
por: Latif, Hira, et al.
Publicado: (2020)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain, Rohit K, et al.
Publicado: (2017)

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
por: Gupta, Neeraj, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective
por: Cranmer, Holly, et al.
Publicado: (2022)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma
por: Gennatas, Spyridon, et al.
Publicado: (2013)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
por: Carcereny, Enric, et al.
Publicado: (2021)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
por: Ali, Robert, et al.
Publicado: (2019)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
por: Sabari, Joshua K, et al.
Publicado: (2017)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Li, Shuluan, et al.
Publicado: (2021)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l6q34vt8hns2cu77jgka3d0t3u